Form 4 for ABT Abbott Laboratories
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001415889-23-003925 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 | 2023-02-28 | ABT | Wellisch Alejandro D | SVP | A - Grant | $0.00 | +10.7K | 50.5K | +27% | $0 | |
| 2023-03-02 | 2023-02-28 | ABT | Wellisch Alejandro D | SVP | F - Tax | $99.77 | -3,730 | 46.8K | -7% | -$372.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2023-02-28 | A | A | 10,650 | $0.00 | 50,482 | D | — | — | (F1) Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. |
| 2 | Common | Common shares without par value | 2023-02-28 | F | D | 3,730 | $99.77 | 46,752 | D | — | — |